Hemp Stocks

  • ACB / Aurora

    Ja, bin auch (wieder) drin. Habe gesehen, dass das Q4/2018 am 25.10.2018 gezeigt wird und das Q1/2019 am 29.10.2018, Highlights *smile* *dirol*


    Und dies ist noch vom Dienstag in dieser Woche, also vom 4.9.18:



    Aurora Cannabis Closes $200 Million Debt Facility with BMO


    Historic Financing with a Canadian Tier 1 Bank Provides Additional Capital to Drive Growth


    EDMONTON, Sept. 4, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that it has closed its previously announced debt facility with the Bank of Montreal ("BMO"). The facility consists of a $150 million term loan and a $50 million revolving credit facility (together, the "Loans"), both of which mature in 2021. Included in the facility is an option to upsize the facility to $250 million total following the implementation of Bill C-45 on October 17, 2018, subject to agreement by BMO and satisfaction of certain legal and business conditions.


    The debt facility is primarily secured by Aurora's production facilities, including Aurora Sky, Aurora Mountain, and Aurora Vie. Strategically located at Edmonton International Airport, Aurora Sky is the world's most technologically advanced cannabis facility, projected to produce in excess of 100,000 kg per year of high-quality, low-cost per gram, cannabis upon completion.


    Management Commentary


    "We are incredibly proud to have successfully closed this historic debt facility supported by a premier Canadian bank, BMO, who understands our needs and potential. This is both a reflection of the rapidly maturing nature of the broader cannabis industry and strong validation of the economic potential of Aurora's best-in-class, technologically advanced production facilities," said Terry Booth, CEO of Aurora. "With BMO and the syndicate lenders, Aurora gains significant runway to expansion opportunities that will positively contribute to our long-term margin profile and provide accelerated entry into multiple international markets. This additional capital positions us well to continue building the pre-eminent global cannabis company with a focus on vertically integrated, geographically and horizontally diversified assets."


    Glen Ibbott, CFO of Aurora, added, "The closing conditions of this debt facility included stringent due diligence of Aurora's current production facilities as well as a thorough review of Aurora's projected revenue growth across all of our divisions. With our extremely strong balance sheet, Aurora is well positioned to execute on our business strategy, including accelerated development and launch of new products, continued rapid expansion of our domestic and international operations, and entry into new global markets."


    Pursuant to the agreed upon conditions of the Loans, Aurora may, at its discretion, repay the balance of the Loans without penalty, at any time. The pricing of the Loans is a set margin over the BMO CAD Prime Rate or a Bankers' Acceptance of appropriate term. Based on the current BMO CAD Prime Rate, the interest payable is expected to be in the mid to high 4% per annum range over the term of the Loans. Additional details on this new sector benchmark debt facility can be found in the Company's documents that have been filed on www.sedar.com.


    About Aurora


    Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 570,000 kg per year and sales and operations in 14 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.


    Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet European Union (EU) GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Europe GmbH, have achieved this level of certification.


    In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 10 companies acquired – MedReleaf, CanvasRx, Peloton Pharmaceutical, Pedanios, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, and Anandia – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Capcium Inc. (private), and Alcanna Inc. (TSX: CLIQ).


    Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.


    For more information about Aurora, please visit our investor website, investor.auroramj.com, Twitter, Facebook or Instagram.


    Terry Booth, CEO
    Aurora Cannabis Inc.


    Forward looking statements

    Emil

  • Aurora

    https://www.stockwatch.com/New…56788&symbol=ACB&region=C


    Aurora erhält eine HealthCanada-Produktionslizenz für seine Aurora Eau Anlage in Lachute/Que.


    Aurora Cannabis Inc. hat für seine Aurora Eau-Anlage in Lachute, Que, eine Health Canada-Produktionslizenz erhalten. Das Unternehmen verfügt nun über sieben Produktionsstätten mit einer Produktionskapazität von über 160.000 Kilogramm pro Jahr. Aurora hat zusätzliche Anlagen in Entwicklung, so dass die gesamte finanzierte Kapazität auf mehr als 500.000 Kilogramm pro Jahr steigt. Darüber hinaus hat Aurora über seine hundertprozentige Tochtergesellschaft Medreleaf Corp. die Lizenz zur Herstellung von Öl für sein Werk in Bradford erhalten, das bei voller Kapazität eine Anbaufläche von 28.000 Kilogramm pro Jahr hat. Medreleaf Bradford verfügt über eine großvolumige Kohlendioxid-Extraktionsanlage, die die Ölproduktion erheblich steigern wird und in Erwartung des Erhalts der Verkaufslizenz erhebliche Mengen an Derivaten vorrätig hält. Aurora Eau, eine 48.000 Quadratfuß große Einrichtung mit einer Produktionskapazität von 4.500 Kilogramm pro Jahr, wurde speziell für die GMP-Standards (Good Manufacturing Practices) der Europäischen Union entwickelt und repräsentiert die nächste Entwicklung der Indoor-Grow-Anlagen von Aurora. Aurora Eau wurde gebaut, um Flexibilität in allen wichtigen Produktionsparametern zu ermöglichen, um die aktuellen exotischen Sorten des Unternehmens sowie neue Stämme, die noch nicht eingeführt wurden, und neue Genetik, die für den medizinischen Gebrauch und den Gebrauch für Erwachsene bestimmt sind, optimal anzupassen. Aurora Eau liegt in Lachute, Que., Und liegt auf einem 46 Hektar großen landwirtschaftlichen Nutzland, das Aurora für 136.000 Dollar für künftige Expansionszwecke erwerben kann. Dies würde die gewichtete Präsenz des Unternehmens in Quebec erweitern und zusätzliche Kapazitäten für die künftige Produktentwicklung und den Vertrieb bieten. Das Unternehmen wird sich wie auch seine anderen Einrichtungen im Rahmen der Verpflichtung des Unternehmens zum Aurora-Standard und zur weiteren Diversifizierung der Lieferkette auf dem Weg zu einer EU-GMP-Zertifizierung fortentwickeln. Bis heute hat Aurora zwei EU-GMP-Anbauanlagen in Kanada sowie eine EU-GMP-zertifizierte Einrichtung in Deutschland, die von ihrer hundertprozentigen Tochtergesellschaft Aurora Europe GmbH betrieben wird, für den Import, die Freisetzung und den Vertrieb von Cannabis. Der Anbau begann in Eau Der Anbau hat bei Aurora Eau begonnen, nachdem eine Mischung aus Klonen und ausgereiften Pflanzen mit einem maßgeschneiderten, umweltfreundlichen Transporter erhalten wurde, der von Auroras hundertprozentiger Tochter B.C. Nordlichter. Der neue Transporter ermöglicht es Aurora, große Mengen von Klonen und Müttern kostengünstig zu transportieren, was eine schnelle Ansiedlung neuer Einrichtungen ermöglicht. Nach dem erfolgreichen Transfer ist Aurora Eau jetzt in voller Produktion. Managementkommentar "Wir sind stolz auf die Errungenschaften von Aurora Eau und mit sieben Produktionslizenzen sind wir außerordentlich gut positioniert, um sowohl auf dem kanadischen als auch auf dem internationalen Markt weiter auf dem Markt zu bestehen", sagte Terry Booth, Chief Executive Officer von Aurora. "Mit der großtechnischen Produktion bei Aurora Sky haben wir die Möglichkeit, die Produktion von Aurora Eau in Nischenmärkten zu investieren, wodurch wir unsere Markenbekanntheit steigern und unser Margenprofil verbessern. Unsere neue Ölproduktionslizenz in Bradford erhöht unsere Produktionskapazität weiter höhermargige Öle und treiben Wachstum. "

  • Aurora-Nes

    von heute, spannend:


    Aurora Cannabis acquires Agropro, Borela hemp outfits


    2018-09-12 08:22 ET - News Release



    Mr. Terry Booth reports


    AURORA CANNABIS ACQUIRES EUROPE'S LARGEST ORGANIC HEMP COMPANY


    Aurora Cannabis Inc. has acquired Europe's largest producer, processor and supplier of certified organic hemp and hemp products, Agropro UAB, as well as hemp processor and distributor Borela UAB.


    Agropro, a hemp seed contracting and processing company, and its sister company Borela UAB, a processor and distributor of organic hulled hemp seeds, hemp seed protein, hemp flour and hemp seed oil, currently has 1,600 hectares (4,000 acres) under contract, potentially yielding more than one million kilograms of organic hemp with additional contracts available to expand to more than 3,000 hectares across Lithuania, Latvia, Estonia and Poland.


    Previously, the companies were focused exclusively on the production and sale of hemp-seed-based products to markets across Europe, North America and Asia. Each year, very substantial quantities of CBD (cannabidiol) containing hemp biomass were left on the field unutilized.


    Postacquisition, Aurora intends to extract, refine and productize the organic hemp biomass into a wide range of organic CBD-based wellness products to generate new and significant revenue streams in this burgeoning market. With increasing recognition of the medical and general health benefits of CBD-based products, Aurora continues executing on a CBD-focused strategy that covers the entire value chain, from supply, through genetics research and clinical trials, to product development and distribution to various domestic and international markets across five continents.


    In addition to the CBD-related market potential, hemp is an increasingly sought-after food supplement and meat substitute for the large and rapidly growing health food, vegetarian and vegan markets, due to its high protein content. Through its majority-owned subsidiary Hempco, Aurora is already executing on a number of hemp food market opportunities, and intends to integrate Agropro's organic supply and distribution with Hempco's to enhance market access and accelerate growth of high-margin, premium hemp-based product offerings.


    On Feb. 1, 2018, Borela's hemp grain processing facility became the only European hemp company to receive a BRC quality certificate, enabling Borela to supply supermarkets with its product. Borela's operations have also received USDA Organic, Eco-Cert, as well as other certifications, enabling the company to market premium products across large markets.


    The organic certification achieved by both Agropro and Borela will enable the launch of new premium products, positively impacting the company's margin profile for hemp-based products.


    Management commentary


    "Agropro's position as Europe's leading producer of premium organic hemp along with the significant and previously unutilized CBD production from the large quantities of currently discarded biomass, makes this an accretive acquisition and one that positions Aurora well to become a global leader in organic CBD-based wellness products," said Terry Booth, chief executive officer.


    Neil Belot, chief global business development officer, added: "With our industry-leading team of crop and plant scientists, extraction and product formulation expertise, and wide-reaching global distribution networks and partnerships, we anticipate increasing production, extraction, refinement and supply of CBD, as well as other hemp-based food products. With a broad European footprint, extensive contracted land agreements and solid existing revenue streams, Agropro and Borela provide further expansion of our international footprint, while playing an important role in the execution of our CBD wellness and hemp-based food products strategy."


    Skirmantas Nikstele, co-founder and chief executive officer of Agropro, added: "As the largest producer, processor and supplier of organic hemp products in Europe, we have developed a strong reputation for quality and consistency with our customers across the globe. Through Aurora, we gain access to a wider distribution network, as well as an access to industry-leading science to help ramp up production, while enhancing margins through the introduction of new products, proven production techniques and robust genetics."


    Hemp -- superfood with high market growth


    The hemp plant is made up of three components. Seeds, which are used in food and personal care products, leaves and flowers, which produce cannabidiol (CBD), used in medical products, supplements and beauty products, and stalk, which produces fibre and hurd, used in paper products, building materials, clothing and other textiles.


    Hemp seed oil offers the richest and most balanced source found in nature of essential fatty acids (EFAs), such as omega 3 and omega 6 oils. EFAs play a very important role in critically important processes, such as detoxification and the formation of brain cells, hormones and neurotransmitters. Hemp seed is not only rich in essential fatty acids, it also represents an important source for amino acids, which are the building blocks of protein. Essential amino acids are not produced by our bodies, and therefore must come from food. Hemp seeds contain all nine essential amino acids, as well as other nutritionally important vitamins and minerals, such as iron, zinc, carotene, vitamin B1, vitamin B2, vitamin B6, vitamin D, vitamin E, calcium, magnesium, potassium and enzymes.


    These characteristics have resulted in strong continued market growth of hemp-based products. Grand View Research (industrial hemp market size, share and trends analysis, 2018) anticipates the industrial hemp market to grow at a compound annual growth rate of 14.0 per cent to $10.6-billion (U.S.) by 2025. The hemp seed market, as a subcategory, is anticipated to show even stronger growth.


    With Agropro and Borela, Aurora has acquired a very substantial supply of organic hemp seed products, as well as the capacity to process the raw material into products, and the international distribution channels to sell these. Market reach will be further strengthened through integration with Hempco, while Aurora's science teams will be spearheading research into cultivation yield enhancements, as well as further medical and wellness applications.


    Terms of the transaction


    Aurora purchased 100 per cent of the issued and outstanding shares of Agropro UAB and Borela UAB for total cash consideration of 5,364,000 euros (approximately $8.1-million (Canadian)) and common shares of Aurora equivalent to 960,000 euros (approximately $1.4-million (Canadian)), based on the five-day volume-weighted average price as of Sept. 10, 2018. In addition, Aurora will also refinance existing debt totalling 2,076,000 euros (approximately $3.1-million (Canadian)) and provide a finder's fee totalling 1,517,400 euros (approximately $2.3-million (Canadian)).


    About Aurora Cannabis Inc.


    Headquartered in Edmonton, Alta., Canada, with financed capacity in excess of 570,000 kilograms per year and sales and operations in 14 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, and wholesale and retail distribution.


    We seek Safe Harbor.


    © 2018 Canjex Publishing Ltd. All rights reserved.

  • Selector hat am 13.09.2018 17:55 geschrieben:

    Quote

    @Petra


    Hast du einen Link zur Info oder den Text. Es wäre nett, wenn wir das sehen könnten. Danke.

    Nationalbank: Jetzt auch Big in Haschisch-Aktien


    12.9.2018 Lukas Hässig


    Währungshüter kaufen alles auf, was ihnen in die Hände kommt – Neuerdings Gross-Aktionärin von „First Cannabis Company“....


    https://insideparadeplatz.ch/2…-big-in-haschisch-aktien/


    .....ich nehme an es stimmt - sonst wäre sicher ein shitstorm losgebrochen.

  • CannabisAktien: Droht ärger aus den USA

    Der Aktionär: http://www.deraktionaer.de/akt…r-aus-den-usa--397050.htm


    Cannabis-Aktien: Canopy Growth, Aurora Cannabis und Co brechen ein – droht Ärger aus den USA?


    Michel Doepke | Redakteur


    14.09.2018 - 08:59 Uhr


    AURORA CANNABIS5,40 € -2,70%CANOPY GROWTH38,90 € -1,44%TILRAY CL.294,70 € -6,45%


    [Blocked Image: http://www.deraktionaer.de/upload_aktionaer/Cannabis-shutterstock_734768755_111993.jpg]


    Die boomende kanadische Cannabis-Industrie scheint den USA ein Dorn im Auge zu sein. Wie das Magazin Politico berichtet, gibt es Überlegungen, gegen Pot-Investoren sowie -Arbeiter ein Einreiseverbot zu verhängen. Die Hintergründe für den Vorstoß liegen auf der Hand: Frisches Öl ins Handelsstreit-Feuer zwischen den USA und Kanada gießen.


    Wie ein hochrangiger Beamter für Grenzkontrollen gegenüber Politicoverlauten ließ, könnten Marihuana-Raucher aus den USA verbannt werden. "Unsere Beamten werden nicht alle Einreisenden fragen, ob sie Marihuana konsumieren. Aber wenn Fragen in diese Richtung führen oder ein entsprechender Geruch aus dem Auto kommt, könnten wir eine Befragung durchführen", so Todd Owen.


    Viel Rauch um wenig


    Den USA geht es weniger um den Cannabis-Konsum an-sich. Eher geht es den Vereinigten Staaten darum, von der boomenden Industrie in Kanada überrollt zu werden. Schließlich wird dem Cannabis-Markt ein Multi-Milliarden-Potenzial nachgesagt. Zudem enstehen eine Vielzahl neuer Arbeitsplätze in der Branche.


    Trotzdem sorgte der Bericht für stark fallende Notierungen bei den Cannabis-Aktien. Canopy Growth verlor im regulären Handel knapp 14 Prozent, Aurora Cannabis neun Prozent. Cronos, auf die sich die Shortseller von Citron Research eingeschossen haben, verlor ebenfalls gut zehn Prozent an Wert. Ein großer Pot-Stock konnte sich, zumindest im regulären Handel, mit einem satten Plus aus der Affäre ziehen: Tilray. Wie das Cannabis-Unternehmen gestern vorbörslich bekannt gab, werde man fortan Cannabisöl und -blüten nach Deutschland liefern. In der Spitze schoss das Papier auf 127,27 Dollar. Ein neues Rekordhoch. Nachbörslich verlor die Tilray-Aktie dann doch über fünf Prozent.


    Nichts für schwache Nerven


    Der Cannabis-Sektor ist in den vergangenen Wochen heiß gelaufen. Kein Wunder, dass die Cannabis-Aktien in der Folge mit satten Kursverlusten reagierten. Davon sollten sich investierte Anleger jedoch nicht verunsichern lassen. Fakt ist: Die Legalisierungswelle rollt, in Kanada wird es am 17. Oktober 2018 soweit sein. DER AKTIONÄR hat in der neuen Ausgabe die Branche genauer unter die Lupe genommen und erklärt in der Story, welche Aktien noch kaufenswert sind. Das ePaper steht Ihnen hier zum Download zur Verfügung.

  • ACB/USA/D. T.

    Ich habe hier noch eine interessante Aussage von Donald Trump:


    “We are looking at letting states decide legalization.


    I will probably end up supporting that, yes. „ D T


    (Wir prüfen, ob Staaten eine Legalisierung zulassen. Ich werde wahrscheinlich am Ende das unterstützen, ja. )


    Aber, man weiss auch, dass er wie die Fahne im Wind ist.


    Quelle: Newsweek vom 31.08.2018 newsweek.com

  • ACB und CocaCola

    CocaCola möchte Cannabis-Drinks herstellen und befindet sich offenbar in Gesprächen mit Aurora. Die Gespräche sollen weit fortgeschritten sein.


    Quelle: ntv


    17.09.2018 20:36


    Offenbar Gespräche mit Aurora


    Coca-Cola will Cannabis-Drinks herstellen


    [Blocked Image: https://apps-cloud.n-tv.de/img/20628034-1537202588000/16-9/750/106698379.jpg]


    Die Gespräche laut Insidern seien "ziemlich weit fortgeschritten".


    (Foto: dpa)


    An alkoholische Getränke hat sich Softdrink-Riese Coca-Cola bereits herangewagt. Nun will der Konzern einem Medienbericht zufolge auch cannabishaltige Drinks entwickeln. Sie sollen gegen Schmerzen und Krämpfe wirken.





    Coca-Cola hat offenbar Interesse am Einstieg in die Herstellung von cannabishaltigen Getränken. Dem kanadische Business-Sender "BNN Bloomberg" zufolge verhandelt der Konzern diesbezüglich mit Aurora, einem der größten kanadischen Cannabis-Hersteller. Die Nachricht versetzte Aurora-Anleger sogleich in einen Kaufrausch: Die Aktien stiegen an der Börse in Toronto um bis zu 22 Prozent auf 10,42 Dollar.



    Coca-Cola und Aurora teilten in getrennten Erklärungen mit, man schaue sich die Entwicklung am wachsenden Markt von mit Marihuana versetzten Getränken genau an. Ansonsten kommentiere man aber keine Marktspekulationen. Auch "BNN Bloomberg" zufolge gibt es keine Garantie dafür, dass die Gespräche erfolgreich verlaufen. Die beiden Unternehmen werden demnach wahrscheinlich aber Drinks entwickeln, die bei Schmerzen, Entzündungen und Krämpfen wirken, meldete der Sender unter Berufung auf Insider. Die Gespräche seien "ziemlich weit fortgeschritten".


    Bei den mit Marihuana versetzten Getränken geht es um den Wirkstoff Cannabidiol (CBD), der als nicht suchtfördernd oder berauschend gilt. Dem Deutschen Hanfverband zufolge gilt CBD zudem als relativ arm an Nebenwirkungen. Als Ausnahmemedikation bei schweren Erkrankungen kann Cannabis in Deutschland seit März letzten Jahres gegen Schmerzen verordnet werden. Aus der Hanfpflanze wird aber auch das "high" machende Tetrahydrocannabinol (THC) gewonnen.


    Kanada und einige US-Bundesstaaten haben Marihuana auch für nicht medizinische Zwecke als Genussmittel legalisiert. Nach dem US-Bundesrecht bleibt der Handel damit aber verboten, weshalb viele US-Konzerne vorsichtig sind.


    Bisher haben sich nur Alkohol-Hersteller auf den Markt vorgewagt. So hat der Hersteller von Corona-Bier Constellation Brands mehr als vier Milliarden Dollar in Canopy Growth - ebenfalls aus Kanada - investiert, um auf Cannabis basierende Getränke zu produzieren. Analysten rechnen nun damit, dass auch der Cola-Rivale Pepsi an dem Markt interessiert sein dürfte.


    CHARTS


    [Blocked Image: https://kursdaten.teleboerse.de/teleboerse/3077/chartNG.gfn?instrumentId=40301409&chartType=0&subProperty=3&width=620&height=410&time=300]
    Aurora Cannabis
    6,59 19,8%


    ftü/DJ

  • Aurora und CocaCola

    Ben hat am 17.09.2018 22:43 geschrieben:


    Hi, da haben noch andere was gecheckt, Quelle Link:


    https://seekingalpha.com/artic…a-cannabis-one-just-right


    Aurora Cannabis: This One Is "Just Right"


    Sep. 18, 2018 10:13 AM ET


    |


    | About: Aurora Cannabis Inc. (ACBFF), KO, Includes: APHQF, CGC, CRON, HMLSF, HYYDF, MJ, TGODF, TLRY


    by: Jonathan Cooper


    [Blocked Image: https://static3.seekingalpha.com/images/users_profile/048/749/491/big_pic.png]


    Jonathan Cooper


    Long/short equity, growth at reasonable price, contrarian, long-term horizon


    Marketplace


    The Growth Operation


    (4,773 followers)


    Summary


    Perhaps Aurora is the "just right" combination of Canopy Growth's execution with HEXO's low price.


    Good execution: deals with major pharmacies, growing medical marijuana sales, supply agreements covering 89% of Canadians.


    I have some concerns about Aurora's acquisition spree.


    A Coca-Cola deal and a US stock listing could be great tailwinds in the coming months.


    I rate Aurora as a buy and it remains a smaller holding in my Model Cannabis Portfolio.


    Looking for a portfolio of ideas like this one? Members of The Growth Operation get exclusive access to our model portfolio. Start your free trial today »


    (All prices are in Canadian dollars.)


    [Blocked Image: https://static.seekingalpha.com/uploads/2018/9/17/48749491-15371990579247437.png]


    (Author based on company filings; some figures are estimates as, e.g., Canopy Growth does not provide production estimates in kg/year)


    Executive Summary


    Aurora Cannabis (ACB.TO) (OTCQX:ACBFF) is the third-largest Canadian cannabis company by enterprise value and the second-largest by production capacity and supply agreements.


    Aurora has grown aggressively through acquisitions. Aurora took an 18% stake in The Green Organic Dutchman (OTCQX:TGODF) in January, acquired CanniMed in March, and MedReleaf in July. The latter two deals were the largest of their kind when they were made. These acquisitions are double-edged: They allow Aurora to expand rapidly, but they present a risk that Aurora may overpay and destroy shareholder value.


    Aurora rose heavily on September 17 on rumors of a deal with Coca-Cola (KO). In the short term, that deal - and whether it happens or not - is likely to have a big impact on Aurora's share prices. Shares gained 17% on the rumor and could fall just as far if KO makes a deal elsewhere. Shares could also rise further if the right deal is announced: Canopy Growth (CGC) rose over 30% on August 15th after the Constellation (STZ) deal.


    In terms of value, Aurora occupies a middle ground in between the inexpensive Aphria (OTCQB:APHQF) and HEXO (OTCPK:HYYDF) and the premium valuations of Canopy Growth, Tilray (TLRY), and Cronos (CRON). Perhaps Aurora is the Goldilocks of Canadian cannabis stocks - a "just right" combination of the value of HEXO with the size and execution (deals in the top four provinces and with large pharmacies) of Canopy Growth.



    und


    https://www.streetinsider.com/…es+%28KO%29/14618584.html


    News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.


    Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM), today is responding to a request from the Investment Industry Regulatory Organization of Canada ("IIROC") regarding media reports with respect to potential partnerships with multiple beverage companies. The Company's policy is not to comment on speculative media reports. The Company does confirm that it engages in exploratory discussions with industry participants from time to time. At this time the Company confirms there is no agreement, understanding or arrangement with respect to any partnership with a beverage company.

    In accordance with applicable disclosure requirements, Aurora will advise the market of material changes when they occur.

    Emil

  • Auroa-News heute

    Aurora / ACB


    News


    Aurora Cannabis Completes Distribution of Australis Capital


    EDMONTON, Sept. 19, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM), today announced that it has completed its previously announced distribution of Australis shares and warrants (the "Distribution"). The distribution was completed on September 19, 2018, and the Australis shares and warrants will commence trading on the CSE under the symbol "AUSA" effective at the market open today.


    In accordance with the terms of the Distribution, eligible Aurora shareholders were paid one unit of Australis for every 34 Aurora shares outstanding as at August 24, 2018 (the "Record Date). Each unit consists of one common share and one share purchase warrant of Australis. Each warrant entitles the holder thereof to acquire one share at an exercise price of $0.25 per Australis share, on or prior to 4:00 p.m. (Eastern Time) on the date that is one year after the Distribution.


    As described in further detail in the Final Prospectus, no units were issued to shareholders who are (or were deemed to be) non-residents of Canada. Rather, such units have been delivered to a custodian for sale in the open market following the Distribution, and the net cash proceeds will be delivered to non-resident shareholders, net of any withholding taxes.


    Following the distribution, Aurora has no direct ownership interest in Australis, and the company is an independently operating entity. Aurora, however, does hold two warrants, allowing the Company to acquire an ownership interest at such time in the future (within 10 years) when holding investments in U.S. cannabis assets will become permissible.


    "With the completion of this distribution we have delivered an immediate return of capital to Aurora shareholders while enabling the Australis team to proceed with their mandate to invest in U.S. cannabis assets with high growth potential," said Terry Booth, CEO of Aurora. "Australis' management, board of directors and investment committee are well positioned to leverage their collective knowledge and extensive experiences to rapidly execute on the tremendous opportunity ahead to generate substantial long-term shareholder value."


    Scott Dowty, CEO of Australis, added, "We will leverage the opportunities created by a fragmented U.S. cannabis market with limited access to growth capital. We have not wasted time and have already identified a number of strong assets within this market that we believe have high growth potential. With the completion of our over-subscribed private placement, we have the funds to start executing on these opportunities immediately and deliver growth."


    About Aurora


    Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per year and sales and operations in 18 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.


    Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet European Union (EU) GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland (formerly Pedanios), have achieved this level of certification.


    In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending acquisition of ICC Labs – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).


    Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.


    For more information about Aurora, please visit our investor website, investor.auroramj.com, Twitter, Facebook or Instagram


    Terry Booth, CEO
    Aurora Cannabis Inc.


    About Australis


    Australis Capital identifies and invests in the cannabis industry predominately in the United States, a highly regulated, fragmented, fast growing and evolving industry. Investments may include and are not limited to equity, debt or other securities of both public and private companies, financings in exchange for royalties or other distribution streams, and control stake acquisitions. Australis Capital adheres to stringent investment criteria and will focus on significant near and mid-term high-quality opportunities with strong return potentials while maintaining a steadfast commitment to governance and community. Australis Capital's Board, Management and Advisory Committee members have material experience with, and knowledge of, the cannabis space in the U.S., extensive backgrounds in highly regulated industries, adherence to stringent regulatory compliance, public company and operational expertise. For more information, please visit us at www.ausacap.com.



    und


    Presse: / Quelle:


    https://www.profitconfidential…-cola-us-listing-october/



    Coca-Cola Partnership


    It’s been a hectic week for marijuana stocks so far, with a lot of news dropping on a variety of fronts. But none has been more impactful than the rumors that The Coca-Cola Co (NYSE:KO) is looking to enter the marijuana industry and could choose Aurora Cannabis Inc (OTCMKTS:ACBFF, TSE:ACB) as its vessel. Needless to say, the potential Coca-Cola partnership proved to be a massive boon to the Aurora stock forecast.


    Reports have come in that Coca-Cola is in talks with Aurora to produce non-alcoholic, cannabis-infused beverages. As a result, Aurora Cannabis stock climbed swiftly, surging 10% when the reports came in, while KO stock hasn’t seen much movement since the talks were announced. (Source: “Coke, Aurora Cannabis in talks to make marijuana-infused drinks: BNN Bloomberg,” CNBC, September 17, 2018.)


    Should the partnership come to fruition, the two would likely develop health-focused beverages that will ease inflammation, pain, and cramping, the report stated.


    “Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD [cannabidiol] as an ingredient in functional wellness beverages around the world,” The Coca-Cola Co said in a statement. “No decisions have been made at this time.”


    Advertisement


    Aurora also declined to give specifics about a potential deal, but did say that it, “has expressed specific interest in the infused beverage space, and we intend to enter that market.” (Source: Ibid.)


    This marks the first time a non-alcoholic beverage company has looked into the marijuana sector.


    Considering how positive investments have been received by the alcohol industry, the soft-beverage sector now looking to enter the marijuana market is only going to drive marijuana stock prices even higher.


    After all, the $3.8-billion investment by Constellation Brands, Inc. (NYSE:STZ) into Canopy Growth Corp (NYSE:CGC) was enough to turn the entire industry around and push dozens of percentage points of growth across multiple stocks.


    Should Coca-Cola be planning to invest, expect to see a major surge in marijuana prices as more concrete details filter out.


    But the potential Coca-Cola deal is not the only positive news to have come out of Aurora Cannabis stock lately.


    While likely to be the most momentous, several other positive moves by the company have brightened the Aurora Cannabis stock forecast considerably.


    Hemp Leadership in Europe


    One of the more recent boons to the Aurora Cannabis stock forecast came by way of the company’s deal with Agropro UAB, Europe’s largest producer, processor, and supplier of organic hemp and hemp products.


    The Agropro acquisition provides Aurora with access to 1,600 hectares of land to grow a potential 1,000,000 kilograms of hemp, while Agropro is also looking into expanding into Lithuania, Latvia, Estonia, and Poland, potentially adding another 3,000 hectares. (Source: “Aurora Cannabis Acquires Europe’s Largest Organic Hemp Company,” Cision, September 12, 2018.)


    The deal will open up Agropro to exploiting the CBD components of its hemp.


    Aurora is planning to use that formerly discarded hemp biomass containing CBD to create a number of wellness products.

  • Aurora Investor Conference Call Sept.25, 2018

    Danke at Tengri Lethos für Video


    Aurora Cannabis to Host Fourth Quarter 2018 Investor Conference Call on September 25, 2018


    TSX: ACB


    EDMONTON, Sept. 21, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM), today announced that it has scheduled its conference call to discuss the results for its fourth quarter ended June 30, 2018. The call will be hosted on Tuesday, September 25th, 2018 at 11:00 a.m. Eastern Timeby Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, and Cam Battley, Chief Corporate Officer followed by a question and answer period.


    CONFERENCE CALL DETAILS

    DATE:

    Tuesday, September 25th, 2018

    TIME:

    11:00 a.m. Eastern Time (9:00 a.m. Mountain Time)

    WEBCAST:

    https://bit.ly/2pnnKkA

    DIAL IN NUMBER:

    (647) 427-7450 or (888) 231-8191

    REPLAY:

    (416) 849-0833 or (855) 859-2056
    Available until 12:00 midnight Eastern Time Tuesday, October 2, 2018

    REFERENCE NUMBER:

    2977713

    About Aurora


    Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per year and sales and operations in 18 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.


    Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet European Union (EU) GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland (formerly Pedanios), have achieved this level of certification.


    In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending acquisition of ICC Labs – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).


    Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.


    For more information about Aurora, please visit our investor website, investor.auroramj.com, Twitter, Facebook or Instagram


    Terry Booth, CEO
    Aurora Cannabis Inc.

  • Cannmart receives Health Canada's first ACMPR sales-only license

    Namaste Technologies Inc. ("Namaste" or the "Company") (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company's wholly-owned subsidiary, Cannmart Inc. ("Cannmart") has received its Access to Cannabis for Medical Purposes Regulations ("ACMPR") medical cannabis "sales-only" license (the "License"), which is the first of its kind to be issued by Health Canada. The License represents the most significant milestone in the history of the Company and is the final component of its strategy for Cannmart to become Canada's leading online platform for medical cannabis.


    Cannmart will operate as an online marketplace for medical cannabis sourced from multiple Licensed Producers, which will offer patients a curated selection of medical cannabis strains in one location. Cannmart has secured over 13 domestic and international supply agreements and will also focus on developing arrangements with micro-cultivators who will provide high-end craft strains, subject to the upcoming regulations of the Cannabis Act. Cannmart's goal is to offer the largest and most diverse selection of medical cannabis products available in the Canadian market.


    Further to the Company's September 18(th) news release, Cannmart will be allowed to buy pre-packaged, labelled and tested cannabis products. This development is very significant for Cannmart in that it will eliminate the need for buying in bulk, testing and packaging which will significantly reduce overhead costs for Cannmart and thus increase gross profit margins and profitability. By allowing Cannmart to purchase pre-packaged medical cannabis products it can remain focused on its areas of expertise in e-commerce and technology, and further expand on the products and services that can be provided through Cannmart.


    Namaste operates the largest global online marketplace for cannabis consumption devices, with over 1.5 million customers globally. The Company has acquired and developed industry-leading technology including its e-commerce AI platform, Findify.io ("Findify") and NamasteMD ("NamasteMD.com"), which is Canada's first medical cannabis consultation app available in both the Apple and Google Play Stores. The Company plans to leverage its e-commerce technology and expertise to provide a unique user experience for each customer. Medical patients acquired through NamasteMD will be able to onboard and purchase products through Cannmart.


    With Namaste's operations in over 20 countries and consumer databases established in strategic regions including the United Kingdom and Australia, the Company is well-positioned to expand on its cannabis platform in launching telemedicine and cannabis e-commerce platforms in global markets where the company maintains strong market share.


    https://technical420.com/canna…-acmpr-sales-only-license